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A B S T R A C T
The human rights issues raised
by the conduct of maternal-fetal
human immunodeficiency virus
transmission trials in Africa are not
unique to either acquired immunodeficency syndrome or Africa, but
public discussion of these trials
presents an opportunity for the
United States and other wealthy
nations to take the rights and welfare of impoverished populations
seriously. The central issue at stake
when developed countries perform
research on subjects in developing
countries is exploitation. The only
way to prevent exploitation of a
research population is to insist not
only that informed consent be
obtained but also that, should an
intervention be proven beneficial,
the intervention will be delivered to
the impoverished population.
Human rights are universal and cannot be compromised solely on the
basis of beliefs or practices of any
one country or group. The challenge to the developed countries is
to implement programs to improve
the health of the people in developing countries both by improving
public health infrastructure and by
delivering effective drugs and vaccines to the people. {Atn J Public
Health. 1998;88:560-563)
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Introduction
Since the adoption of the Universal
Declaration of Human Rights by the United
Nations General Assembly in 1948, the
countries of the world have agreed that all
humans have dignity andrights.In 1998, the
50th anniversary of the Universal Declaration of Human Rights, the Declaration's
aspirations have yet to be realized, and
poverty, racism, and sexism continue to conspire to frustrate the worldwide human
rights movement. The human rights and
public health issues of maternal-fetal human
immunodeficiency virus (HIV) transmission
prevention trials in Africa, Asia, and the
Caribbean are not unique to acquired
immunodeficiency syndrome (AIDS) or to
those countries. Open discussion of these
issues provides an opportunity to move the
real human rights agenda forward.' This is
why Global Lawyers and Physicians (GLP),
a transnational organization dedicated to
promoting and protecting the health-related
provisions of the Universal Declaration of
Human Rights, joined with Ralph Nader's
Public Citizen organization to challenge the
conduct of a series of AIDS clinical trials in
these developing countries^ (S. M. Wolfe et
al., written communication to Secretary of
Health and Human Services Donna Shalala,
April 22, 1997).

their newborns for 6 weeks reduced the
incidence of HIV infection by two thirds
(from about 25% to about 8%).^ Six months
after stopping the study, the US Public
Health Service recommended the ACTG
076 regimen as the standard of care in the
United States." In June 1994, the World
Health Organization (WHO) convened a
meeting in Geneva at which it was concluded (in an unpublished report) that the
076 regime was not feasible in the developing world. At least 16 randomized clinical
trials (15 using placebos as controls) were
subsequently approved for conduct in
developing countries, primarily in Africa.
These trials involve more than 17 000 pregnant women. Nine of the studies, most of
them comparing shorter courses of zidovudine, vitamin A, or HIV immunoglobulin
with placebo, are fimded by the Centers for
Disease Control and Prevention (CDC) or
the National Institutes of Health (NIH).^
Most of the public discussion about
these trials has centered on the use of placebos.'^'''* The question of placebo use is a
central one in determining how a study
should be conducted. But we believe the
more important issue these trials raise is the
question of whether they should be done at
all. Specifically, when is medical research
ethically justified in developing countries
that do not have adequate health services (or
on US populations that have no access to
basic health care)? This question is espe-

The Clinical Trials
In 1994, the first effective intervention
to reduce the perinatal transmission of HIV
was developed in the United States in AIDS
Clinical Trials Group (ACTG) Study 076.
In that trial, use of zidovudine administered
orally to HIV-positive pregnant women as
early as the second trimester of pregnancy,
intravenously during labor, and orally to
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cially pertinent since February 1998 when,
on the basis of a Thailand study that demonstrated that a short course of zidovudine
reduced HIV transmission by 50%, CDC,
NIH, and the United Nations Program on
AIDS (UNAIDS) officials announced that
they would recommend that the use of
placebo be halted in all mother-to-fetus
transmission studies.'

Research on Impoverished
Populations
The central issue involved in doing
research with impoverished populations is
exploitation. Harold Varnius, speaking for
NIH, and David Satcher, speaking for CDC,
both seem to realize this. They wrote in the
New England Journal ofMedicine last year
that "trials that make use of impoverished
populations to test drugs for use solely in
developed countries violate our most basic
understanding of ethical behavior."* However, instead of trying to demonstrate how
the study interventions, such as a shorter
course of zidovudine (AZT), could actually
be delivered to the populations of the countries in the studies, they assert that the studies can be justified because they will provide infonnation that the host country can
use to "make a sound judgment about the
appropriateness and financial feasibility of
providing the intervention.'"' However,
what these countries require is not good
intentions, but a real plan to deliver the
intervention, should it be proven beneficial.
Unless the interventions being tested
will actually be made available to the
impoverished populations that are being
used as research subjects, developed countries are simply exploiting them in order to
quickly use the knowledge gained fi-om the
clinical trials for the developed countries'
own benefit. If the research reveals regimens of equal efficacy at less cost, these
regimens will surely be implemented in the
developed world. If the research reveals the
regimens to be less eificacious, these results
will be added to the scientific literature, and
the developed world will not conduct those
studies. Ethics and basic human rights principles require not a thin promise, but a real
plan as to how the intervention will actually
be delivered. Actual delivery is also, of
course, required to support even the utilitarian justification for the trials, which is to
find a simple, inexpensive, and feasible
intervention in as short a time fi-ame as possible because so many people are dying of
AIDS. No justification is supportable unless
the intervention is actually made widely
available to the relevant populations.
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TABLE 1 - H e a l t h Care Expenditures of African Countries Involved in IViother-toChild HIV Transmission Prevention Trials
Country (Year)

Per Capita (US dollars)

Burkina Faso (1992)
Cote d'lvoire (1995)
Ethiopia (1990)
Kenya (1992)
Malawi (1990)
Tanzania (1990)
Uganda (1994)
Zimbabwe (1991)

As % of GDP*

5.5

22
22
5
13
11
5
10
86

3.4
3.9
2.5
5.0
5.0
3.9
6.5

Data from World Bank Sector Strategy, Healthm Nutrition, and Population, 1997.
*GDP = gross domestic product.

Neither NIH nor CDC (nor the host
countries) has a plan that would make the
interventions they are studying available in
Africa, where more than two thirds of the
people in the world reside who are infected
with HIV.' As an example, Varmus and
Satcher point out that the wholesale cost of
zidovudine in the 076 protocol is estimated
to be in excess of $800 per mother and
infant and that this amount is far greater than
what most developing countries can pay for
standard care.* The CDC estimates the cost
of the "short course" zidovudine regimens
being investigated to be roughly $50 per person. The cost of merely screening for HIV
disease, a precondition for any course of
therapy, is approximately $10, and all pregnant women must be screened to find the
cases to treat. These costs must be compared
with the total per capita health care expenditures of the countries where this research
is being conducted (Table 1). Given this fact,
African countries involved in the clinical
trials (or some other fiinder) must make realistic assurances that if a research regimen
proves effective in reducing mother-to-fetus
transmission of HTV, resources will be made
available so that the HIV-positive pregnant
women in their countries will receive this
regimen.
However, the mere assertion that the
interventions will be feasible for use in the
developing countries is simply not good
enough, given our experience and knowledge of what happens in Africa now. For
example, we already know that effectively
treating sexually transmitted diseases such
as syphilis, gonorrhea, and chancroid with
the simple and effective treatments that are
now available can drastically lower the incidence of HTV infection. Yet, these inexpensive and effective treatments are not delivered to poor AfHcans. For example, a recent
study showed that improving the treatment
of sexually transmitted diseases in rural
Tanzania could reduce HIV infections by
40%.* Nonetheless, this relatively inexpen-

sive and effective intervention is not delivered. Vaccines against devastating diseases
have also been developed with sub-Saharan
African populations as test subjects.
Nonetheless, even though vaccines such as
the group A meningococcal meningitis vaccine are inexpensive and effective, they are
not adequately delivered to the relevant subSaharan Afincan populations.'

Cultural Relativism or Universal
Human Rights?
In their article in the New England
Journal of Medicine, Varmus and Satcher
sought to bolster their ethical position by
quoting the chair of the AIDS Research
Committee of the Uganda Cancer Institute,
who wrote in a letter to Dr. Vannus:
These are Ugandan studies conducted by
Ugandan investigators on Ugandans.... It is
not NIH conducting the studies in Uganda,
but Ugandans conducting their study on their
people for the good of their people.

Two points are especially striking
about Varmus' and Satcher's using this justification. First, their justification is simply
not accurate. If NIH and CDC were not
involved in these studies, these agencies
would not have to justify them; indeed, the
studies would not have been undertaken.
These US agencies are involved—these trials are not just Ugandans doing research on
other Ugandans. Second, and more importantly, the use of this quotation implies support for an outdated and dangerous view of
cultural relativism.
Even if it were true that the studies in
question were done by Ugandans on Ugandans, this would not mean that the United
States or the intemational community could
conclude that they should not be criticized.
(This rationale did not inhibit criticism of
apartheid in South Africa, genocide in
Rwanda, or torture and murder in the
Congo.) Human Rights Watch, referring to
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repression in Central Africa, said in its
December 1997 review ofthe year on the
issue of human rights that the slogan
"African solutions to African problems" is
now used as a "thin cover" for abusing citizens.'" That observation can be applicable to
experimentation on citizens as well.
The other major justification both NIH
and CDC use for the trials is the consensus
reached at the June 1994 meeting of
researchers at WHO. Ofthe many analogies
that have been drawn between the HIV
transmission prevention trials and the US
Public Health Service's Tuskegee syphilis
study, perhaps most striking is their reliance
on professional consensus instead of ethical
principle to justify research on poor, black
populations. As historian James Jones
wrote in his book Bad Blood, which was
written about the Tuskegee experiment:
"The consensus was that the experiment
was worth doing, and in a profession whose
members did not have a well-developed
system of normative ethics, consensus
formed the functional equivalent of moral
sanction.""
Neither researcher consensus nor host
country agreement is ethically sufficient
justification for choosing a research population. As the National Research Council's
Committee on Human Genome Diversity
properly put it, in the context of intemational research on human subjects, "[sjensitivity to the specific practices and beliefs of
a community cannot be used as a justification for violating universal human rights."'^
Justice and equity questions are also important to the ability of individual research
subjects to give informed consent.

Informed Consent
Research subjects should not be drawn
from populations who are especially vulnerable (e.g., the poor, children, or mentally
impaired persons) unless the population is
the only group in which the research can be
conducted and the group itself will derive
benefits from the research. Even when these
conditions are met, informed consent must
also be obtained.'•''''* In most settings in
Afiica, voluntary, informed consent will be
problematic and difficult, and it may even
preclude ethical research. This is because,
in the absence of health care, virtually any
offer of medical assistance (even in the
guise of research) will be accepted as "better than nothing" and research will almost
inevitably be confused with treatment, making informed consent diificult.
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Interviews with women subjects of the
placebo-controlled trial in the Ivory Coast
support this conclusion. For example, one
subject, Cecile Guede, a 23-year-old HIVinfected mother participating in a USfinanced trial, told the New York Times,
"They gave me a bunch of pills to take, and
told me how to take them. Some were for
malaria, some were for fevers, and some
were supposed to be for the virus. I knew
that there were different kinds, but I figured
that if one of them didn't work against
AIDS, then one ofthe others would."" The
Times reporter who wrote the front-page
story, Howard W. French, said, "For Ms
Guede, the reason to enroll in the study last
year was clear: it offered her and her infant
free health care and a hope to shield her
baby from deadly infection. . . . [T]he
prospect of help as she brought her baby
into the world made taking part in the
experiment all but irresistible."''
Persons can make a gift of themselves
by volunteering for research. However, it is
extremely unlikely that poor African
women would knowingly volunteer to participate in research that oifered no benefit to
their communities (because the intervention
would not be made available) and that
would only serve to enrich the multinational drug companies and the developed
world.'^ Thus, a good ethical working rule
is that researchers should presume that
valid consent cannot be obtained from
impoverished populations in the absence of
a realistic plan to deliver the intervention to
the population. Informed consent, by itself,
can protect many subjects of research in
developed countries, but its protective
power is much more compromised in
impoverished populations who are being
offered what looks like medical care that is
otherwise unavailable to them.

The International Community
and the AIDS Pandemic
If the goal of the clinical trials is to
reduce the spread of HIV infection in developing countries, what strategy should public health adopt to achieve this end? It is not
obvious that the answer is to conduct clinical trials of short-term zidovudine treatment. In the developed world, for example,
HIV-infected women are advised not to
breast-feed their infants because 8% to 18%
of them will be infected with HIV from
breast milk.'* However, in much ofthe
developing world, including in most
African countries, WHO continues to rec-

ommend breast-feeding because the lack of
clean water still makes formula-feeding
more dangerous. As long as this recommendation stays in effect, and is followed, even
universal use of the ACTG 076 regimen,
which would lower the overall newborn
infection rate by about 16%, would only
likely serve to reduce the incidence of HIV
infection in infants by about the same
amount that it is increased by breast-feeding (8% to 18%). A more effective public
health intervention to improve the health of
women and their children may be to put
more efforts into providing clean water and
sanitation. This will help not only to deal
with HIV, but also to alleviate many other
problems, including diarrheal diseases.
President Jacques Chirac of France
was on target in his December 1997 speech
to the 10th International Conference on
Sexually Transmitted Disease and AIDS in
Africa, which was held in the Ivory Coast.
President Chirac proposed creating an international "therapy support fund" that is primarily funded by European countries (the
former colonial powers in Africa)."
Although he put emphasis on the new drugs
available for AIDS treatments, it would be
more useful to consider the public health
priorities of the countries themselves, for
example, prevention, especially in areas
such as sanitation, water supply, nutrition,
education, and the delivery of simple and
effective vaccines and medical treatments
for sexually transmitted diseases.

Conclusion
Actual delivery of health care requires
more than just paying lip service to the
principles of the Universal Declaration of
Human Rights; it requires a real commitment to human rights and a willingness on
the part of the developed countries to take
economic, social, and cultural rights as seriously as political and civil rights. D
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